Q-omics provides the consensus-scored STX8 profile across patient tissues and cancer cell-line models. STX8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, STX8 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, STX8 RNA expression shows 18,485 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where STX8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX8 survival associations across molecular data types. STX8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX8 RNA expression–survival associations across cancer types. High STX8 expression shows unfavorable associations in HNSC, KICH and STAD, but favorable associations in BRCA, UCEC and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for STX8 RNA expression.
This table summarizes STX8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STX8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX8 shows lower tumor expression in KICH, LUSC, UCEC and BRCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher STX8 RNA expression in tumor versus normal tissue (log2 FC = +0.371, t-test p < 0.001).
This table shows molecular features associated with STX8 in patient tissues and cancer cell lines. In patient samples, STX8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STX8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
